Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response

被引：0
|
作者：
Saad, F [1 ]
机构：
[1] Univ Montreal, Dept Urol Surg, Ctr Hosp, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 01期
关键词：
D O I：
10.1093/jnci/dji017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [21] Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients
    Gianfilippo Bertelli
    Abdelhamid Heouaine
    Giuseppe Arena
    Ambrogio Botto
    Ornella Garrone
    Ida Colantonio
    Marcella Occelli
    Elena Fea
    Silvia Giubergia
    Marco Merlano
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 46 - 51
  • [22] Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients
    Bertelli, G
    Heouaine, A
    Arena, G
    Botto, A
    Garrone, O
    Colantonio, I
    Occelli, M
    Fea, E
    Giubergia, S
    Merlano, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 46 - 51
  • [23] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
  • [24] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
  • [25] Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid
    Olson, KB
    Hellie, CM
    Pienta, KJ
    UROLOGY, 2005, 66 (03) : 658E1 - 658E3
  • [26] New hope for patients with metastatic hormone-refractory prostate cancer
    de Wit, Ronald
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (15) : 817 - 823
  • [27] Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
    Rosen, PJ
    Mendoza, EF
    Landaw, EM
    Mondino, B
    Graves, MC
    McBride, JH
    Turcillo, P
    deKernion, L
    Belldegrun, A
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1626 - 1636
  • [28] Zoledronic acid has long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer
    Coleman, R.
    Rosen, L.
    Zheng, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 127 - 128
  • [29] Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Saad, F
    Schulman, KA
    JOURNAL OF UROLOGY, 2004, 171 (04): : 1537 - 1542
  • [30] Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
    Hortobagyi, GN
    Theriault, RL
    Lipton, A
    Porter, L
    Blayney, D
    Sinoff, C
    Wheeler, H
    Simeone, JF
    Seaman, JJ
    Knight, RD
    Heffernan, M
    Mellars, K
    Reitsma, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2038 - 2044
12345